Literature DB >> 12720215

Chronic graft-versus-host disease.

Stephanie J Lee1, Georgia Vogelsang, Mary E D Flowers.   

Abstract

Chronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allogeneic stem cell transplantation. Mild forms of chronic GVHD are often manageable with local or low-dose systemic immunosuppression and do not affect long-term survival. In contrast, more severe forms of chronic GVHD require intensive medical management and adversely affect survival. This report reviews current concepts of the pathogenesis, clinical risk factors, classification systems, organ manifestations, and available treatments for chronic GVHD. It also provides a comprehensive listing of the published clinical trials aimed at prevention and primary treatment of chronic GVHD. Copyright 2003 American Society for Blood and Marrow Transplantation

Entities:  

Mesh:

Year:  2003        PMID: 12720215     DOI: 10.1053/bbmt.2003.50026

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  268 in total

1.  Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.

Authors:  Zoya Kuzmina; Verena Gounden; Lauren Curtis; Daniele Avila; Tiffani Taylor Rnp; Judy Baruffaldi; Edward W Cowen; Haley B Naik; Sarfaraz A Hasni; Jacqueline W Mays; Sandra Mitchell; Kristin Baird; Seth M Steinberg; Steven Z Pavletic
Journal:  Am J Hematol       Date:  2014-11-24       Impact factor: 10.047

2.  Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  M Y Detrait; S Morisset; R Peffault de Latour; I Yakoub-Agha; R Crocchiolo; R Tabrizi; J-O Bay; P Chevalier; F Barraco; N Raus; S Vigouroux; L Magro; M Mohty; N Milpied; D Blaise; G Socié; M Michallet
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

Review 3.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

4.  Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.

Authors:  Vikas Gupta; Martin S Tallman; Wensheng He; Brent R Logan; Edward Copelan; Robert Peter Gale; Hanna J Khoury; Thomas Klumpp; John Koreth; Hillard M Lazarus; David I Marks; Rodrigo Martino; David A Rizzieri; Jacob M Rowe; Mitchell Sabloff; Edmund K Waller; John F DiPersio; Donald W Bunjes; Daniel J Weisdorf
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

5.  High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.

Authors:  Shih Hann Su; Valérie Martel-Laferrière; Annie-Claude Labbé; David R Snydman; David Kent; Michel Laverdière; Claire Béliveau; Tanya Logvinenko; Sandra Cohen; Silvy Lachance; Thomas Kiss; Jean Roy
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-25       Impact factor: 5.742

Review 6.  Overview of T-cell depletion in haploidentical stem cell transplantation.

Authors:  Nicola Daniele; Maria Cristina Scerpa; Maurizio Caniglia; Chiara Ciammetti; Cecilia Rossi; Maria Ester Bernardo; Franco Locatelli; Giancarlo Isacchi; Francesco Zinno
Journal:  Blood Transfus       Date:  2012-01-24       Impact factor: 3.443

7.  Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models.

Authors:  D Kim; H-H Won; S Su; L Cheng; W Xu; N Hamad; J Uhm; V Gupta; J Kuruvilla; H A Messner; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

8.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

9.  Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis.

Authors:  Fevzi F Yalniz; Mohammad H Murad; Stephanie J Lee; Steven Z Pavletic; Nandita Khera; Nilay D Shah; Shahrukh K Hashmi
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-14       Impact factor: 5.742

10.  Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.

Authors:  Hideki Nakasone; Lu Tian; Bita Sahaf; Takakazu Kawase; Kelsi Schoenrock; Spenser Perloff; Christine E Ryan; Jed Paul; Rakesh Popli; Fang Wu; Joanne M Otani; John Coller; Edus H Warren; David B Miklos
Journal:  Blood       Date:  2015-03-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.